WO2006036003A1 - 生体特異的親和性を有する物質を結合した微粒子及びその使用 - Google Patents
生体特異的親和性を有する物質を結合した微粒子及びその使用 Download PDFInfo
- Publication number
- WO2006036003A1 WO2006036003A1 PCT/JP2005/018399 JP2005018399W WO2006036003A1 WO 2006036003 A1 WO2006036003 A1 WO 2006036003A1 JP 2005018399 W JP2005018399 W JP 2005018399W WO 2006036003 A1 WO2006036003 A1 WO 2006036003A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- segment
- polyethylene glycol
- substance
- fine particles
- integer
- Prior art date
Links
- 239000000126 substance Substances 0.000 title claims abstract description 58
- 239000011859 microparticle Substances 0.000 title claims abstract description 39
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 58
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 34
- 229920000642 polymer Polymers 0.000 claims abstract description 34
- 239000010419 fine particle Substances 0.000 claims description 60
- 239000002245 particle Substances 0.000 claims description 21
- 239000012736 aqueous medium Substances 0.000 claims description 18
- 229920000768 polyamine Polymers 0.000 claims description 16
- 230000005291 magnetic effect Effects 0.000 claims description 14
- 239000004816 latex Substances 0.000 claims description 13
- 229920000126 latex Polymers 0.000 claims description 13
- 125000006850 spacer group Chemical group 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 239000000696 magnetic material Substances 0.000 claims description 12
- 125000003827 glycol group Chemical group 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 230000027455 binding Effects 0.000 claims description 9
- 238000006116 polymerization reaction Methods 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002344 surface layer Substances 0.000 claims description 8
- 230000009870 specific binding Effects 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 150000004703 alkoxides Chemical class 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 150000002334 glycols Chemical class 0.000 claims description 4
- 239000010954 inorganic particle Substances 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 238000002407 reforming Methods 0.000 claims 2
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 8
- 239000000470 constituent Substances 0.000 abstract 1
- 239000006249 magnetic particle Substances 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 238000000926 separation method Methods 0.000 description 11
- 239000000284 extract Substances 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000013076 target substance Substances 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- -1 polyoxyethylene chain Polymers 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000001226 reprecipitation Methods 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- LSHROXHEILXKHM-UHFFFAOYSA-N n'-[2-[2-[2-(2-aminoethylamino)ethylamino]ethylamino]ethyl]ethane-1,2-diamine Chemical compound NCCNCCNCCNCCNCCN LSHROXHEILXKHM-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000002109 Argyria Diseases 0.000 description 4
- 239000007987 MES buffer Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 229910044991 metal oxide Inorganic materials 0.000 description 3
- 150000004706 metal oxides Chemical class 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- MUXOBHXGJLMRAB-UHFFFAOYSA-N Dimethyl succinate Chemical compound COC(=O)CCC(=O)OC MUXOBHXGJLMRAB-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940095102 methyl benzoate Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001662443 Phemeranthus parviflorus Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- XRFJZINEJXCFNW-UHFFFAOYSA-N [Zn+2].[O-][Mn]([O-])(=O)=O Chemical compound [Zn+2].[O-][Mn]([O-])(=O)=O XRFJZINEJXCFNW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- NLWBJPPMPLPZIE-UHFFFAOYSA-N methyl 4-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CBr)C=C1 NLWBJPPMPLPZIE-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- IJJSYKQZFFGIEE-UHFFFAOYSA-N naphthalene;potassium Chemical compound [K].C1=CC=CC2=CC=CC=C21 IJJSYKQZFFGIEE-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- YPNZYYWORCABPU-UHFFFAOYSA-N oxiran-2-ylmethyl 2-methylprop-2-enoate;styrene Chemical group C=CC1=CC=CC=C1.CC(=C)C(=O)OCC1CO1 YPNZYYWORCABPU-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
Definitions
- Fine particles bound with a substance having biospecific affinity and use thereof Fine particles bound with a substance having biospecific affinity and use thereof
- the present invention provides a pair of bio-specific affinities.
- a member of a substance having a substance for example, an antibody, an antigen, a fine particle bound with a nucleic acid, etc., which is contained in a biological sample.
- the present invention relates to use for detecting, separating and purifying members, and to the fine particles.
- biological samples biological samples
- a separation carrier for example, an antibody capable of specifically binding to a target drug
- a sequence complementary to a nucleic acid having the target sequence When the target substance is a cell, the factor or the antibody that specifically binds to the cell or the ligand is immobilized on a water-insoluble solid phase carrier.
- the separated single unit is used.
- a separation carrier is packed in a column, it has an affinity for the antibody, ligand, etc. and can bind specifically. Is added to the column to bring the substance into contact with a separation carrier to form a complex of the substance with the antibody, ligand, etc., and washed with a buffer or the like as appropriate.
- the complex is dissociated and the substance is eluted and obtained, for example, with a buffer with high ionic strength, a surfactant solution, or a buffer with very high or low pH.
- Affinity chromatographies that contain are widely used. This affinity chromatography is very selective and effective, utilizing specific interactions between the target substance and the solid phase, eg, ligand. It is a purification method.
- the above-mentioned complex is formed on a microparticle carrier such as microsphere, and the separation carrier is recovered by centrifugation or the like, and if necessary, washed with a buffer or the like as appropriate. Later, if necessary, separation by affinity, for example, by placing the complex in a buffer with very high ionic strength or a buffer with very high or low pH. There is also a method of dissociating and eluting the target substance bound on the carrier.
- the target substance for example, a specific protein is separated and recovered, and is examined by electrophoresis, Western plot, etc.
- This method is called immunoprecipitation, and is a very useful means for detecting trace proteins from cell extracts.
- impurities are often non-specifically adsorbed on the surface of the microsphere used as a solid phase carrier, resulting in poor separation efficiency.
- Reference 4 Is bound to a latex particle at one end of a polyoxyethylene chain described in WO 2 0 4/0 5 6 8 9 5 A1 (hereinafter referred to as Reference 4)
- examples thereof include latex particles that can carry ligand or the like on the other end of the chain.
- Document 1 describes a microsphere in which a physicoactive substance is bound to a styrene-glycidyl methacrylate polymer via a spacer. It has been suggested that this microsphere has an advantage in that it can efficiently and specifically bind to a substance in a biological sample having affinity for the substance having the physiological activity.
- Reference 2 describes magnetic particles that consist of a magnetic material coated with a metal oxide that is different from the magnetic material, with nucleic acid adsorbed on the surface.
- Document 3 describes magnetic polymer particles in which particles made of a magnetic metal or metal compound are coated with a polymer, on which a specific antibody is adsorbed on the surface.
- such a magnetic particle is further added to a phosphate physiological saline containing 0.5% ushi serum albumin (BSA) and 0.1% polyethylene glycol. Also listed is a microparticle that has been shaken and dispersed in a buffer solution and then gently shaken at room temperature for 30 minutes to adsorb the antibody and block the particle surface with albumin. .
- BSA ushi serum albumin
- the microparticles described in any one of References 1 to 3 are used from biological samples other than the target, that is, those of interest, proteins, lipids, inorganic salts, etc.
- biological samples other than the target that is, those of interest, proteins, lipids, inorganic salts, etc.
- the particles may easily aggregate and settle. In some cases, the rate dropped.
- Fine particles obtained by blocking the surface of the particles in Reference 3 with albumin can suppress the nonspecific adsorption to some extent, and the particles described in Reference 4 further suppress the nonspecific adsorption. be able to.
- the fine particles described in Reference 3 can further suppress the non-specific adsorption, or the fine particles described in Reference 4 can be obtained by another preparation method. Or have a different structure, but the same or better than the fine particles Providing microparticles with specific adsorption characteristics will contribute to the advancement of this technical field.
- a ligand or an antibody described in Reference 1, Reference 2, or Reference 3 also including polymer particles containing a magnetic substance described in the reference cited in Reference 3
- the fine particles bound through a spacer are made of polyethylene glycol (sometimes abbreviated as “PE G”) so that the chains can move freely in an aqueous medium.
- PE G polyethylene glycol
- a fine particle in which one member of a substance having a pair of bio-specific affinity is bound to the surface directly or via a spacer is bound to the surface directly or via a spacer.
- a polymer derivative containing a polyethylene glycol segment is directly bonded to the surface, and the polyethylene glycol chain in the derivative can freely move in an aqueous medium.
- the microparticles in the form contain the other member of the substance having the biospecific affinity, and the substance suspected of non-specifically binding to the microparticles.
- microparticles contain the other member of the substance having biospecific affinity, and the microparticles in the sample suspected of having non-specific binding to the microparticles. Use for a carrier to form a selective bond between the other member and the one member on the microparticle,
- a substance having a pair of biospecific affinity referred to in the present invention is not limited, but is an antibody and an antigen (or hapten), a drug (or ligand) and its receptor (expressing a receptor).
- a single-stranded RNA or a polynucleotide with its complementary nucleotide arrangement IJ, an enzyme and its substrate, and a sugar and a lectin, etc. Can be mentioned.
- a compound or a substance that is a member of any one of the pair forming between the substances is physically or chemically applied to the surface depending on the characteristics of the fine particle surface. Combined. Bonding may also be accomplished via a spacer.
- spacers may be, for example, ethylene dust as described in Table 1.
- a member of a pair of substances having biospecific affinity is bound to a microparticle, in particular a covalent bond.
- the ethylene glycol can be an oligoethylene glycol such as di-, tri- or tetra-ethylene glycol, and the functional group is replaced by a glycidyl group, a hydroxy group, It can be an amino group, a carboxyl group or a sulfo group.
- a high molecular weight molecule such as an antibody is bound to a microparticle, the antibody can be bound directly to the microparticle as long as the binding properties of the molecule to the antigen are not adversely affected.
- Such fine particles are selected from the group consisting of the above-mentioned literature 1, literature 2, literature 3 and the known fine particles cited in them, and can be used for the purpose of the present invention. Any fine particles, if any, are included. Therefore, by citing, the matters described in Documents 1 to 3 are the contents of this specification.
- such fine particles have an average particle size of 0.02 ⁇ ! ⁇ 5 mm, preferably 0.0 5 ⁇ ! ⁇ 1 0 0 ⁇ .
- the fine particles may be directly bonded to a polymer-derived polymer containing a polyethylene glycol segment (physical, for example, ionic bond, hydrogen bond, hydrophobic bond, etc. Or by chemistry, in particular by covalent bonds, and is in a form in which the polyethylene glycol chains in the derivatives are free to move in aqueous media.
- aqueous media buffer solutions, biological samples such as blood, urine, body fluids, cell debris-containing buffers, These aqueous solutions, diluents, aqueous suspensions, and the like that meet the purpose of the present invention, such as cell extracts.
- Polyethylene glycol is a form in which the recall chain can move freely in such an aqueous medium.
- polyethylene glycol chain that is not bonded to (or non-attached to) the fine particles is in the aqueous medium. W; preferably in a state in which the brush structure composed of a polyethylene glycol chain can substantially cover the surface of the fine particles that are not bonded to the members bonded to the fine particles. It means being in a state. It is well known in the art that a polyethylene glycol chain having a plurality of polyethylene glycol chains on its surface can have a brush structure in a k-type medium. It is used in such a well-known sense.
- the polyethylene glycol derivative has a polyethylene glycol segment having a degree of polymerization of 2 to 10 O 0 0, preferably 4 0 to 5 0 0, and a polymer length on the surface of the fine particles. It has a residue or a molecular part that constitutes a site or region that can be bound so that the recall chain can be held or fixed in such a way as to freely move in an aqueous medium.
- a site or region is a segment made of origo or polyamine, and can be a block copolymer of polyethylene glycol and polyamine.
- the polyamine segment can be a polymer segment represented by the following general formulas (1) and (2):
- n represents an integer of 1 ⁇ 1 0, n is 1: Represents an integer of L 0 0, and 1 E ⁇ Pi 1 2, independently of one another, also a hydrogen atom is properly carbon atoms Is an alkyl group of 1 to 5.
- X + y is an integer from 1 to 30 and R 1 ⁇ ! I 4 each independently represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms.
- Fine particles (hereinafter also referred to as PEG-modified fine particles) having such a polyethylene dallic derivative bound to the surface, and particularly preferred are one member of a pair of substances having biospecific affinity directly.
- a polymer derivative containing a polyethylene glycol segment is bonded to the surface through a spacer and the polyethylene glycol chain moves in an aqueous medium.
- Latex particles that are directly bonded fine particles, and in which the fine particles are embedded in a magnetic material or in a surface layer A polymer having a carboxyl group on the latex surface, and a polymer derivative having a polyethylene glycol segment and a polyamine segment, which is a polyethylene glycol segment. Having a polymerization degree of 2 to 100 and a polyamine segment is represented by the general formula (2);
- R 1 ⁇ ! 4 may include fine particles, each of which is independently a hydrogen atom or an alkylene quinole having 1 to 5 carbon atoms.
- the PEG-modified microparticles are bound to the surface of one of a pair of substances having biospecific affinity, which are separated in an aqueous medium, directly or via a spacer.
- a polymer derivative containing a polyethylene glycolate segment in the aqueous medium and binding the polymer derivative to the surface of the microparticles, and a pair of biospecific affinities
- One member of the substance having the above can be conveniently produced by a method of modifying the surface of the fine particles bonded to the surface directly or via a spacer.
- the fine particles are latex particles in a form in which a magnetic substance is embedded or in the form of a surface layer, or the magnetic substance is covered with silica or metal alkoxide.
- Inorganic particles in a covered form preferably latex particles embedded in a magnetic material or in a form having a surface layer, and having a carboxyl group on the surface of the lattice.
- the polymer derivative is a copolymer having a polyethylene glycol segment and a polyamine segment, and the polyethylene glycol segment has a degree of polymerization of 2 to 100 0 0 0
- the polyamine segment has the following general formulas (1) and (2):
- n represents an integer of 1 to 100
- R 2 independently of each other, have a hydrogen atom or a carbon atom number of 1 to 5
- x + y is an integer from 1 to 30 and Ri to R4 each independently represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms. It is preferable to use a polyamine represented by the general formula (2).
- the step of bringing the fine particles into contact with the polymer derivative and the step of bonding the polymer derivative to the surface of the fine particles adversely affect the binding characteristics of one member to the other member in an aqueous medium.
- the polymer derivative is merely subjected to physical bonds such as ionic bonds, hydrogen bonds, and hydrophobic bonds, or a combination of two or more of these at the temperature below room temperature.
- a condensation dehydrating agent for example, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (ED C), N
- the PEG-modified microparticles have specific affinity with one member on the microparticle, and include a specific partner or another member that forms a complex, and Samples suspected of having non-specifically binding substances to the microparticles, especially biological samples such as blood, urine, body fluids, cell lysate-containing buffers, cell extracts, etc. themselves, Alternatively, when they are contacted in a diluted or buffered aqueous medium, the one member on the microparticle can selectively form a bond with the other member, so in the sample. It can be used in a method of forming a specific binding pair with one member of a substance having a biospecific affinity of the pair. Such use can detect the other member present in the sample, It can be used for purification or to provide a method for screening substances that form the bond.
- the bound substance is centrifuged and the particles to be used are If it is a magnetic particle, it is collected by applying a magnetic field, washed with water or a suitable buffer solution, and non-specifically adsorbed impurities are washed away, and then the bound substance is ionic strength.
- the target substance can be isolated from the body.
- a method for detecting or separating or purifying the other member present in the sample using PEG-modified microparticles or a substance that forms the bond is used.
- a screening method is provided.
- a method for forming a specific binding pair with one member of the pair of biospecific affinity substances bound on the microparticle is not limited. However, it can be carried out by incubating the PEG-modified microparticles added to the sample at room temperature for an appropriate time, usually 1 to 24 hours.
- a fine particle having a specific ligand bound to its surface preferably, a magnetic particle is provided with a substance having the biospecific affinity from a sample.
- An operation of separating the target substance from the magnetic particles may be performed by removing the non-specifically bound impurities by performing selective separation and magnetic separation and washing.
- the PE G-modified fine particles have excellent dispersibility under physiological conditions, high ionic strength, and the property that they are difficult to settle even under contaminants such as proteins. The binding efficiency with molecules having affinity is extremely high, and the yield and purity of purification can be improved.
- the magnetic substance that imparts magnetism to the fine particles can be used of any kind or origin as long as it meets the purpose of the present invention, but is limited to a metal oxide having magnetic responsiveness.
- examples include metal oxides such as iron, cobalt, and nickel, and ferromagnetic iron oxides such as magnetite, maghemite, and zinc manganate ferrite are particularly preferred. It can be cited as a thing.
- the PEG-modified microparticles consist of a PEG solution for modifying magnetic particles and an unmodified microparticle, an extraction buffer solution, a washing buffer solution, and an elution buffer solution. It can also be used.
- FIG. 1 is a photograph showing a comparison of dispersibility after cell extract treatment when PEG-modified magnetic particles (A), BSA (B), and gelatin (C) of the present invention are used.
- FIG. 2 shows the results of immunoprecipitation performed using magnetic particles coated with PEG-modified magnetic particles (A), BSA (B), and gelatin (C) of the present invention.
- A PEG-modified magnetic particles
- B BSA
- C gelatin
- Fig. 3 shows a comparison of recovery rates from cell extracts containing the same concentration of ⁇ -fetoprotein (APT) when the magnetic particles of the present invention and BSA-coated magnetic particles are used. It is a photograph showing the result of the stamp mouth.
- APT ⁇ -fetoprotein
- NX-PEG (1) Manufacture of an oligoamine-polyethylene dallic copolymer (hereinafter abbreviated as NX-PEG (1))
- THF dehydrated tetrahydrofuran
- an initiator Add lmmol (80.4 ⁇ L) of 2-methoxyethanol, add 1 mmol of potassium naphthalene (2.86 mL of 0.35 mol / L THF solution), stir for 10 minutes with a magnetic stirrer, and alkoxide.
- 114 mmol (about 5.7 mL) of distilled ethylene oxide (hereinafter abbreviated as EO) was added with a cooled glass syringe and stirred at room temperature for 24 hours to perform ring opening polymerization of E0.
- EO distilled ethylene oxide
- MeO-PEG-Methylbenzoate Abbreviated as MeO-PEG-Methylbenzoate.
- 50 mL of Nasflask was charged with 6.2 mL (263 mmol) of the above MeO-PEG-Methylbenzoate lg (263 ⁇ mol) and pentaethylene hexamine (hereinafter abbreviated as PEHA) corresponding to 100 times the amount of PEG.
- PEHA pentaethylene hexamine
- the mixture was stirred for 24 hours at 120 ° C in a hot water bath to introduce oligoamine at the PEG end. After dissolving the reaction solution in a small amount of methanol, it is dropped into cooled isopropyl alcohol (hereinafter abbreviated as IPA).
- IPA cooled isopropyl alcohol
- N 5 -PEG MeO-PEG-Phenyl-N5 (hereinafter abbreviated as N 5 -PEG)) was obtained.
- MeO-PEG-NH 2 manufactured by Nippon Oil & Fats Co., Ltd .: SUNBRIGHT MEPA-50H
- lg 196 ⁇ mol
- dimethyl succinate having two methinoesters in the molecule
- the precipitate is collected by centrifugation (4 ° C or less, 5, 00 rpm, 20 minutes), dissolved in a small amount of methanol again, and purified by IPA reprecipitation three times in total, which is unreacted. Dimethyl succinate was completely removed. The precipitate was recovered by benzene freeze-drying to obtain a PEG derivative (MeO-PEG-NHC OCH 2 CH 2 COOCHs) at one end.
- Magnetic particles with carboxyl groups on the surface Magnetic material is coated with a resin based on polystyrene: solid concentration 10% / PBS dispersion; manufactured by JSR, Tokyo, Japan) 150 1 50 mM 2-morpho Renoethane Norenophonic acid (hereinafter abbreviated as MES) Noffer (pH 5.0) After dispersion in 1.0 ml, the magnetic particles were collected with a magnet and the supernatant was removed. This operation was repeated once more to wash the magnetic particles.
- MES 2-morpho Renoethane Norenophonic acid
- each of these magnetic particles coated with PEG® BSA and gelatin was compared in terms of dispersibility when treated with cell extracts.
- the magnetic particle dispersion 50 1 was placed in an Eppendorf tube, and after removing the supernatant, ⁇ ⁇ of cell extract (NIH 3T3) was added, stirred, and shaken for 1 hour at room temperature to react. After removing the supernatant, the dispersibility after washing once with 20 mM Tris-HCl 150 mM NaCl (pH 8.0) and 0.05% Tween20 (TBST) was compared.
- the protein was transferred from a gel after SDS-PAGE electrophoresis to a polyvinylidene difluoride (PVDF) membrane. Transcription was performed at a constant current of 1 mA per cm 2 for 2 hours. Thereafter, the mixture was blocked in a 1% BSA / PBS solution for 30 minutes, and further anti-AFP rabbit antibody (1% BSA / PBS solution) diluted 5000 times was shaken at room temperature for 1 hour. After washing 3 times with TBST, Al force phosphatase-labeled anti-rabbit antibody (goat) diluted 5000 times with 10 BSA / PBS solution was added, and the mixture was allowed to stand at 4 ° C for 1 hour. After washing 3 times with TBST, 5-bromo-4-chloro "3-mdolyl-phosphate / Nitro blue
- the reaction was carried out in a terazolium (B CIP / NBT) substrate solution.
- PEG-modified magnetic fine particles with fixed ligands do not contain non-specific contaminants, and have a high yield and a high yield compared to conventional magnetic particles. It can be used for separation and purification of high purity biological materials. Therefore, the present invention can be used in the medical industry.
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006537856A JPWO2006036003A1 (ja) | 2004-09-28 | 2005-09-28 | 生体特異的親和性を有する物質を結合した微粒子及びその使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004329734 | 2004-09-28 | ||
JP2004-329734 | 2004-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006036003A1 true WO2006036003A1 (ja) | 2006-04-06 |
Family
ID=36119124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/018399 WO2006036003A1 (ja) | 2004-09-28 | 2005-09-28 | 生体特異的親和性を有する物質を結合した微粒子及びその使用 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2006036003A1 (ja) |
WO (1) | WO2006036003A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8962342B2 (en) | 2007-06-06 | 2015-02-24 | Beckton, Dickinson And Company | Near-infrared dyes as surface enhanced raman scattering reporters |
JP2016090570A (ja) * | 2014-11-04 | 2016-05-23 | 三洋化成工業株式会社 | 磁性シリカ粒子を用いた対象物質の分離方法 |
CN112710826A (zh) * | 2020-11-17 | 2021-04-27 | 北京九强生物技术股份有限公司 | 一种提高试剂稳定性的包被和封闭方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001200050A (ja) * | 2000-01-17 | 2001-07-24 | Japan Science & Technology Corp | ポリエチレングリコール化金属、金属酸化物または半導体超微粒子 |
WO2002096977A1 (fr) * | 2001-05-30 | 2002-12-05 | Nanocarrier Co., Ltd. | Procede de liaison d'une substance a incorporer a une terminaison polymere |
JP2004177402A (ja) * | 2002-11-12 | 2004-06-24 | Matsushita Electric Ind Co Ltd | 特異結合反応測定方法、それに用いる試薬キットおよび特異結合反応測定装置 |
JP2004226384A (ja) * | 2003-01-27 | 2004-08-12 | Foundation For Advancement Of Science & Technology | 核酸検出用チップおよびその使用方法 |
JP2004528834A (ja) * | 2001-03-08 | 2004-09-24 | ファルマ・ジェン・ソシエダード・アノニマ | リガンドの固定化 |
-
2005
- 2005-09-28 JP JP2006537856A patent/JPWO2006036003A1/ja active Pending
- 2005-09-28 WO PCT/JP2005/018399 patent/WO2006036003A1/ja active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001200050A (ja) * | 2000-01-17 | 2001-07-24 | Japan Science & Technology Corp | ポリエチレングリコール化金属、金属酸化物または半導体超微粒子 |
JP2004528834A (ja) * | 2001-03-08 | 2004-09-24 | ファルマ・ジェン・ソシエダード・アノニマ | リガンドの固定化 |
WO2002096977A1 (fr) * | 2001-05-30 | 2002-12-05 | Nanocarrier Co., Ltd. | Procede de liaison d'une substance a incorporer a une terminaison polymere |
JP2004177402A (ja) * | 2002-11-12 | 2004-06-24 | Matsushita Electric Ind Co Ltd | 特異結合反応測定方法、それに用いる試薬キットおよび特異結合反応測定装置 |
JP2004226384A (ja) * | 2003-01-27 | 2004-08-12 | Foundation For Advancement Of Science & Technology | 核酸検出用チップおよびその使用方法 |
Non-Patent Citations (1)
Title |
---|
ISHII T ET AL: "Preparation of functionally Pegylated gold nanoparticles with narrow distribution through autoreduction of auric cation by alpha-biotinyl-PEG-block-[poly(2- (N,N-dimethylamino)ethyl methacrylate)].", LANGMUIR., vol. 20, no. 3, 3 February 2004 (2004-02-03), pages 561 - 564, XP002988206 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8962342B2 (en) | 2007-06-06 | 2015-02-24 | Beckton, Dickinson And Company | Near-infrared dyes as surface enhanced raman scattering reporters |
US9546957B2 (en) | 2007-06-06 | 2017-01-17 | Becton, Dickinson And Company | Near-infrared dyes as surface enhanced raman scattering reporters |
JP2016090570A (ja) * | 2014-11-04 | 2016-05-23 | 三洋化成工業株式会社 | 磁性シリカ粒子を用いた対象物質の分離方法 |
CN112710826A (zh) * | 2020-11-17 | 2021-04-27 | 北京九强生物技术股份有限公司 | 一种提高试剂稳定性的包被和封闭方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006036003A1 (ja) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Khumsap et al. | Epitope-imprinted polymers: applications in protein recognition and separation | |
CN101632019B (zh) | 蛋白质固定化支持体及其制造方法 | |
JP5344511B2 (ja) | 被覆磁性粒子の調製方法 | |
JP6532202B2 (ja) | 磁性粒子、リガンド結合粒子、標的物質の検出又は分離方法、及び前記磁性粒子の製造方法 | |
JP4567627B2 (ja) | 核酸分離方法および核酸分離用の固体基板 | |
JP6453590B2 (ja) | 固相担体、リガンド結合固相担体、標的物質の検出又は分離方法、及び前記固相担体の製造方法 | |
JP6618916B2 (ja) | 固相担体、リガンド結合固相担体、標的物質の検出又は分離方法、及び前記固相担体の製造方法 | |
JP5866880B2 (ja) | 生理活性物質固定化用粒子、生理活性物質固定粒子及び糖親和性物質捕捉粒子 | |
JP2009292804A (ja) | リガンド分子固定ポリマー、リガンド分子固定粒子、標的物質の検出方法および標的物質の分離方法 | |
JP6289608B2 (ja) | 固相担体、リガンド結合固相担体、標的物質の検出又は分離方法、固相担体の製造方法、及びリガンド結合固相担体の製造方法 | |
WO2006036003A1 (ja) | 生体特異的親和性を有する物質を結合した微粒子及びその使用 | |
JP6203295B2 (ja) | 標的物質捕獲方法、標的物質捕獲用の固相担体及び当該固相担体の製造方法 | |
CN118307681A (zh) | 经修饰的免疫磁珠、其制备方法及应用 | |
JP4903449B2 (ja) | 磁性複合体およびその製造方法、マンノースを表面に有する物質の除去方法及びマンノースを表面に有する物質の濃縮方法 | |
JP6660935B2 (ja) | 固相担体、リガンド結合固相担体、標的物質の検出又は分離方法、及び前記固相担体の製造方法 | |
JP6230997B2 (ja) | 金属/金属酸化物表面に対する分子結合のための新しい方法 | |
Zourna | Smart magnetic affinity adsorbents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006537856 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |